Zimmer Biomet Holdings, Inc. $ZBH Shares Purchased by Strs Ohio

Strs Ohio boosted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 222,744 shares of the medical equipment provider’s stock after acquiring an additional 8,009 shares during the period. Strs Ohio owned 0.11% of Zimmer Biomet worth $20,029,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Rakuten Investment Management Inc. acquired a new stake in Zimmer Biomet in the third quarter valued at $37,307,000. Sector Gamma AS raised its holdings in Zimmer Biomet by 28.0% in the third quarter. Sector Gamma AS now owns 113,478 shares of the medical equipment provider’s stock valued at $11,178,000 after acquiring an additional 24,847 shares in the last quarter. SG Americas Securities LLC raised its holdings in Zimmer Biomet by 29.2% in the third quarter. SG Americas Securities LLC now owns 61,110 shares of the medical equipment provider’s stock valued at $6,019,000 after acquiring an additional 13,812 shares in the last quarter. Border to Coast Pensions Partnership Ltd raised its holdings in shares of Zimmer Biomet by 6.5% during the third quarter. Border to Coast Pensions Partnership Ltd now owns 360,462 shares of the medical equipment provider’s stock worth $35,506,000 after purchasing an additional 22,104 shares during the period. Finally, National Pension Service raised its holdings in shares of Zimmer Biomet by 4.5% during the third quarter. National Pension Service now owns 393,476 shares of the medical equipment provider’s stock worth $38,757,000 after purchasing an additional 16,928 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Up 0.2%

Shares of NYSE:ZBH opened at $83.07 on Monday. The stock has a market capitalization of $16.08 billion, a price-to-earnings ratio of 21.58, a price-to-earnings-growth ratio of 1.91 and a beta of 0.48. Zimmer Biomet Holdings, Inc. has a 1-year low of $79.83 and a 1-year high of $108.29. The company’s fifty day moving average is $92.53 and its two-hundred day moving average is $92.68. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The business had revenue of $2.09 billion for the quarter, compared to analysts’ expectations of $2.07 billion. During the same quarter last year, the company earned $1.81 EPS. The company’s revenue for the quarter was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.47 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, April 30th. Investors of record on Tuesday, March 31st were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend was Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is 24.94%.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 2,650 shares of the stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the sale, the senior vice president owned 10,224 shares of the company’s stock, valued at $967,803.84. This trade represents a 20.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.28% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

ZBH has been the topic of a number of research reports. UBS Group reissued a “sell” rating and set a $89.00 target price on shares of Zimmer Biomet in a report on Wednesday, February 11th. Stifel Nicolaus dropped their target price on shares of Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating on the stock in a report on Wednesday, April 29th. JPMorgan Chase & Co. dropped their target price on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating on the stock in a report on Wednesday, April 29th. Evercore raised shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and increased their target price for the stock from $94.00 to $120.00 in a report on Monday, January 5th. Finally, The Goldman Sachs Group cut shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 target price on the stock. in a report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $102.43.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.